Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
News|Articles|March 11, 2025
Aging Population, Burnout Continue to Drive Oncology Workforce Shortage
Author(s)Tony Berberabe, MPH
Fact checked by: Morgan Bayer
Julie Gralow, MD, shed light on the factors contributing to the growing shortage of oncologists in the US and what can be done to address it.
Advertisement
Advertisement
As the demand for cancer care continues to rise, the US is facing a growing shortage of oncologists. Julie Gralow, MD, chief medical officer at the American Society of Clinical Oncology (ASCO), recently shed light on the factors contributing to this crisis and what can be done to address it. Gralow discussed the challenges of burnout, the impact of administrative burdens, and the need for systemic changes to support oncologists and improve patient care during an interview with Targeted Oncology.
Related to this article
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
The phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202) is exploring alisertib plus paclitaxel in small cell lung cancer after immunotherapy and chemotherapy.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement